

## Xbrane Biopharma Q4 2023 - Navigating muddy waters

Redeye comments on Xbrane's year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights issue which has had large implications on the share price.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Xbrane Biopharma Q4 2023 - Navigating muddy waters](#)